Bal Pharma Ltd

Bal Pharma Management Change

Bal Pharma Limited announced a change in designations for directors Ravindra Kumar Kothari and Virupakshaya Himesh, effective October 1, 2026.

Bal Pharma Annual General Meeting

Bal Pharma Ltd held its 39th Annual General Meeting on September 24, 2026, where shareholders transacted all business items as per the notice.

Bal Pharma Price Movement Clarification

Bal Pharma has clarified that the recent significant movement in its share price is purely market-driven and not due to any undisclosed price-sensitive information.

Bal Pharma Other Announcement

Bal Pharma Ltd has filed its quarterly shareholding pattern for the period ended March 31, 2026, in compliance with SEBI regulations.

Bal Pharma Capital Structure Change

Bal Pharma Ltd allotted 10,00,000 convertible warrants to its promoter, Mr. Shailesh Siroya, at ₹84 per warrant. This preferential issue aggregates to ₹8.4 Crore.

Value

₹8.40 Cr

Bal Pharma Dividend

Bal Pharma Limited has fixed September 17, 2026, as the record date for a final dividend of Rs. 1.20 per share. Payment is scheduled for September 24.

Bal Pharma Annual Report

Bal Pharma Limited has filed its Annual Report for the financial year 2025-26 along with the Notice of the 39th Annual General Meeting.

Bal Pharma Annual General Meeting

Bal Pharma Limited will hold its 39th Annual General Meeting on September 24, 2026. The record date for the final dividend is September 17, 2026.

Bal Pharma Capital Structure Change

Bal Pharma Limited clarified the 18-month tenure for utilizing net proceeds from its preferential warrant allotment. There is no change in the objects of the issue.

Execution

18 months

Bal Pharma Other Announcement

Bal Pharma Ltd has filed its quarterly shareholding pattern for the period ending December 31, 2025. This disclosure provides details on share distribution among promoters and public.

Bal Pharma Management Change

Bal Pharma Limited announced changes in director designations, effective October 1, 2026. These changes were approved during the board meeting held on August 12, 2026.

Bal Pharma Merger & Restructuring

Bal Pharma is incorporating a new Joint Venture in the Philippines to distribute pharmaceutical products. The company will hold a 65% equity stake in this entity.

Bal Pharma Q1 FY27 Results: Net Profit ₹1.1 Cr, Up 450.0% YoY

Bal Pharma Ltd reported revenue from operations of ₹88.6 Cr (+34.4% YoY) and net profit of ₹1.1 Cr (+450.0% YoY) for Q1 FY27.

Key figure

Net profit ₹1.1 Cr · +450.0% YoY

Bal Pharma Annual General Meeting

Bal Pharma Ltd released the Scrutinizer's Report on postal ballot voting results regarding the proposed preferential issue of 1,000,000 warrants to the promoter.

Bal Pharma Capital Structure Change

Bal Pharma's shareholders approved a special resolution via postal ballot to issue 10,00,000 warrants to the promoter on a preferential basis.

Bal Pharma Board Meeting Date

Bal Pharma Limited has scheduled a board meeting on August 12, 2026, to consider and approve its unaudited standalone and consolidated financial results for Q1/2026-27.

Bal Pharma Annual General Meeting

Bal Pharma Limited has provided shareholders an opportunity to submit comments or modify their votes regarding a recent corrigendum to a previously issued postal ballot notice.

Bal Pharma Other Announcement

Bal Pharma Ltd has filed its quarterly shareholding pattern for the period ending June 30, 2026, as required by SEBI regulations.

Bal Pharma Annual General Meeting

Bal Pharma issued a corrigendum to its Postal Ballot notice, revising the preferential warrant issue price from ₹81 to ₹84 per warrant.

Value

₹8.40 Cr

Bal Pharma Other Announcement

BAL PHARMA Ltd filed its quarterly shareholding pattern for Q2 FY2026. The filing details promoter and shareholder holdings without any monetary transaction.

Bal Pharma Annual General Meeting

Bal Pharma issued a Postal Ballot notice for shareholder approval. The agenda includes issuing 10,00,000 warrants to promoters on a preferential basis.

Bal Pharma Annual General Meeting

Bal Pharma issued a Postal Ballot Notice to approve a Rs. 8.1 Crore preferential warrant issue to its promoter. Warrants are convertible within 18 months.

Value

₹8.10 Cr

Execution

18 months

Bal Pharma Management Change

Mr. Shreepada ML has commenced duties as Company Secretary and Compliance Officer. The appointment is effective from June 23, 2026.

Bal Pharma Dividend

Bal Pharma Limited recommended a final dividend of Re.1.20 per equity share for FY 2025-2026. The record date for payment will be announced later.

Bal Pharma Q4 FY26 Results: Net Profit ₹3.6 Cr, Down 33.3% YoY

Bal Pharma Ltd reported revenue from operations of ₹84.1 Cr (+2.7% YoY) and net profit of ₹3.6 Cr (-33.3% YoY) for Q4 FY26.

Key figure

Net profit ₹3.6 Cr · -33.3% YoY

Bal Pharma Financial Results

Bal Pharma Ltd approved its FY2026 audited financial results and recommended a 12% dividend. The board also approved a preferential issue of 10,00,000 warrants to promoters.

Bal Pharma Fund Raise

Bal Pharma will consider a proposal for fund raising through preferential warrants to promoters. The board meeting is scheduled for May 27, 2026.

Bal Pharma Legal & Regulatory

Bal Pharma Ltd received notices for governance non-compliances, incurring fines totalling ₹0.23 Crore. The company has paid penalties to both exchanges and rectified committee compositions.

Value

₹0.23 Cr

Bal Pharma Board Meeting Date

Bal Pharma scheduled a board meeting for May 27, 2026, to approve audited financial results and recommend a dividend. The trading window remains closed until May 29.

Bal Pharma Management Change

Bal Pharma announced the resignation of Company Secretary and Compliance Officer Mr. Abdul Basith. He was relieved from services effective May 11, 2026.